Sign in
NBIX Stock Price, Chart, Stats & News
Neurocrine Biosciences, Inc.
Save
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a dividend.
14.40B
Market cap
20.69x
Current P/E
14.12x
Forward P/E
NBIX chart
Fundamentals
Gross margin | 98.18% |
Operating margin | 21.64% |
Pretax margin | 24.66% |
Net margin | 16.73% |
Effective tax rate | 32.15% |
ROA | 10.33% |
ROE | 16.67% |
D/E | 0.13x |
Interest coverage ratio | – |
NBIX valuation
P/E | 20.69x |
P/S | 4.50x |
P/B | 3.92x |
P/CF | 16.31x |
P/FCF | 17.20x |
P/OCF | 16.31x |
PEG | 2.25x |
EV multiple | 18.32x |
About
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia.
Similar securities
Based on sector and market capitalization
Report issue